Tuesday, May 10, 2011 8:42:51 AM
G Clermont1, J Kellum1, J Bartels2, S Chang2, C Chow1 and Y Vodovotz1
1 University of Pittsburgh, Pennsylvania, USA
2 Immunetrics, Inc., Pittsburgh, Pennsylvania, USA
From 24th International Symposium on Intensive Care and Emergency Medicine
Brussels, Belgium. 30 March – 2 April 2004
Critical Care 2004, 8(Suppl 1):P149doi:10.1186/cc2616
Published: 15 March 2004
Objective
Very high or sustained high levels of the inflammatory cytokines tissue necrosis factor (TNF) and interleukin (IL)-6 are believed to be responsible for adverse clinical effects in patients undergoing cardiopulmonary bypass (CPB). We explored, using a mathematical model, whether modulation of this response might be beneficial.
Methods
We developed a mathematical model of the acute inflammatory response that was calibrated from rat endotoxemia and hemorrhagic shock data. The model accommodates a variety of initiators of acute inflammation, provides a dynamic profile of serum markers of inflammation over time, and expresses outcome in as global tissue dysfunction. Irreversible dysfunction is interpreted as death. We constructed a population of 100,000 cases that differed by level of initial stress and propensity to mount an inflammatory response. Initial stress was chosen to result in 4% cohort mortality and to last less than 6 hours, such as CPB. The intervention consisted of the removal of circulating TNF, IL-6 and IL-10 over a period of 6 hours, during which stress was inflicted and acute inflammation triggered. We equated the degree of removal of cytokines to that observed with the application of a biocompatible adsorbent polymer hemoperfusion column in endotoxemic rats.
Results
Death correlated to serum IL-6 and to a lesser degree TNF cumulative levels. Patients with the highest levels of IL-6 6–24 hours after the insult are those that will go on to die (Fig. 1). Examination of the results show that, if the IL-6 levels were decreased by > 60% and TNF levels by > 50% in the period at or shortly after the CPB, over 99% of all patients would survive, compared with 96% in the control arm.
Conclusions
Global, nonspecific, reduction of inflammation improves outcome in simulations of an acute inflammatory challenge such as CPB.
http://ccforum.com/content/8/s1/p149
Recent CTSO News
- CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India • GlobeNewswire Inc. • 11/11/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 09:10:58 PM
- CytoSorbents Reports Third Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 11/07/2024 09:05:00 PM
- CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification • GlobeNewswire Inc. • 11/04/2024 12:00:00 PM
- FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review • GlobeNewswire Inc. • 10/22/2024 11:00:00 AM
- CytoSorbents to Report Third Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 10/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 01:00:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 01:00:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 09:25:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/01/2024 09:22:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 12:06:10 PM
- CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update • GlobeNewswire Inc. • 10/01/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/01/2024 04:15:18 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/26/2024 09:05:05 PM
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM